Table 1.
Patient and disease characteristics
| Characteristics | n (%) of patients or median [range] of values |
|---|---|
| No. patients | 57 (100) |
| Non-Caucasian | 5 (9) |
| Hispanic or Latino | 1 (2) |
| At initial prostate cancer diagnosis | |
| Age (y) | 61 [44–80] |
| PSA (ng/mL), n = 46 | 16 [3–1,549] |
| Gleason score | |
| 4–6 | 14 (25) |
| 7 | 16 (28) |
| 8–9 | 20 (35) |
| Unknown | 7 (14) |
| Prior treatments | |
| Duration of primary ADT (y), n = 54 | 3.4 [0.2–15.5] |
| LHRH agonist | 51 (89) |
| Orchiectomy | 4 (7) |
| Antiandrogens (any) | 52 (91) |
| Bicalutamide | 51 (89) |
| Nilutamide | 6 (11) |
| Flutamide | 5 (9) |
| Finasteride | 2 (4) |
| Estrogens (including estramustine) | 8 (14) |
| Chemotherapy | 3 (5) |
| At registration | |
| Age (y) | 68 [48–90] |
| Years since diagnosis | 6.6 [0.3–20] |
| ECOG performance status 1 | 16 (28) |
| PSA (ng/mL) | 24 [3.7–2,740] |
| PSA doubling time (mo), n = 51* | 2.4 [1–24] |
| Alkaline phosphatase (units/L) | 84 [30–527] |
| Hemoglobin (g/dL) | 13.1 [10.7–15.6] |
| Type of disease | |
| Measurable disease | 20 (35) |
| Measurable only | 6 (11) |
| Measurable and nonmeasurable | 14 (25) |
| Nonmeasurable disease only | 28 (49) |
| PSA only | 9 (16) |
| Sites of disease (multiple) | |
| Viscera | 6 (11) |
| Soft tissue | 6 (11) |
| Lymph nodes | 23 (40) |
| Bone | 40 (70) |
*
PSA doubling time was calculated as natural log2 divided by the slope of the linear regression of natural log of PSA versus time using the three PSA values that confirmed progressive CRPC by PSA progression before study entry.
Abbreviation: ECOG, Eastern Cooperative Oncology Group.